Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia

Completed · Phase 4

Conditions studied: Pneumonia, Bacterial, Community-acquired

In brief

This study will further analyze the use of ceftaroline for CABP and compare its potential to eradicate bacterial pathogens to standard fluoroquinolone therapy. The enhanced spectrum of ceftaroline compared to levofloxacin may be further highlighted from this investigation.

Key facts

Study ID

NCT01524302

Run by

Gary E. Stein, Pharm.D.

People needed

12

Starts

2012-02-01

Expected to finish

2015-04-01

Last updated by the study team

2016-04-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• non-pregnant adults (≥ 18 years old) with suspected CABP admitted to the hospital for parenteral antibiotic therapy.
• All patients will have a creatinine clearance (CrCl) >50 ml/min.

You may not qualify if…

• pregnant or nursing patients,
• allergy to penicillin/cephalosporin antibiotics,
• allergy to fluoroquinolones,
• renal or hepatic failure, or have received an antimicrobial in past 96h.
• Patients who require antibiotics other than the study drugs will also be excluded.

Where it is running

• Sparrow Hospital — Lansing, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.